EP4 Receptor Antagonist for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for EP4 receptor-associated diseases such as rheumatoid arthritis, aortic aneurysms, endometriosis, and ankylosing spondylitis often come with adverse effects, and there is a need for a safer and more effective therapeutic option that specifically targets the EP4 receptor without affecting other pathways.
Innovation Solution
A novel heterocyclic compound with EP4 receptor antagonistic action, represented by the formula (I), which is used as a medicament for the prophylaxis or treatment of these diseases, offering a targeted approach to inhibit IL-23 and IL-6 production and reduce inflammatory pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If NSAIDs or COX-2 inhibitors are used to treat EP4 receptor-associated diseases, then inflammatory pain and symptoms are relieved, but adverse effects occur due to imbalance in arachidonic acid pathway metabolites (e.g., TXA2 and PGI2)
Solution Approach 1:
The patent extracts the therapeutic action from the broad COX pathway inhibition and focuses it specifically on the EP4 receptor. By using a selective EP4 antagonist, the compound blocks only the harmful EP4-mediated inflammation and pain while leaving other prostaglandin pathways (EP1-3) and other metabolites (TXA2, PGI2) unaffected, thus eliminating the adverse effects caused by global COX inhibition.
Solution Approach 2:
The patent applies local quality by targeting a specific receptor subtype (EP4) within the broader prostaglandin system. This selective targeting allows the compound to exert its anti-inflammatory and analgesic effects specifically at the EP4 receptor level without disrupting the balance of other prostaglandin pathways, thereby achieving pain relief without the systemic adverse effects of non-selective COX inhibitors.
2Object-affected harmful factors
If hormonal therapy is used to treat endometriosis, then disease conditions are controlled, but side effects occur including pseudomenopause and decreased bone density due to suppression of estrogen production
Solution Approach 1:
The patent extracts the therapeutic mechanism from estrogen suppression and replaces it with EP4 receptor antagonism. The compound works by blocking the EP4 receptor-mediated signaling pathways that drive endometriosis progression, thereby controlling disease symptoms without interfering with estrogen production or causing pseudomenopause and bone density loss.
Solution Approach 2:
The patent uses an intermediary mechanism (EP4 receptor antagonism) to achieve endometriosis treatment without direct estrogen suppression. The compound acts as a mediator that blocks the harmful EP4 signaling downstream of estrogen, allowing disease control while preserving normal estrogen function and avoiding the associated side effects.
3Object-affected harmful factors
If COX-2 inhibitors are used to relieve pelvic pain in endometriosis, then pain is effective, but severe side effects occur including gastrointestinal injury, nephropathy, and increased cardiovascular risk
Solution Approach 1:
The patent extracts the analgesic effect from non-selective COX inhibition and isolates it to EP4 receptor blockade. This selective approach maintains effective pain relief while avoiding the gastrointestinal, renal, and cardiovascular toxicities associated with broad COX-2 inhibition, as the compound does not interfere with protective prostaglandin pathways.
Solution Approach 2:
The patent applies local quality by directing the therapeutic action specifically to the EP4 receptor in the context of endometriosis pain. This localized receptor targeting achieves potent analgesia without the systemic COX inhibition that causes gastrointestinal and cardiovascular damage, thereby providing pain relief with a safer profile.
Data Source
Figure 1
Figure 2
AI summary
The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm (e.g. abdominal aortic aneurysm, thoracic aortic aneurysm, thoracoabdominal aortic aneurysm etc.), endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.